Reliability analysis of GEM® Premier™ technology: a multicenter study

This paper describes how specific blood gas analyzer characteristics can support the emerging clinical and organizational user's needs while ensuring patient safety. A oneyear data set from two Italian hospitals was analyzed from 10 different blood gas analyzers. Performance measurements in terms of mean down time (MDT) were calculated to show how technical characteristics declared by the manufacturer compare to the analyzer availability in real clinical settings. Results show a high level of reliability for the analyzed technology, associated with very low MDT of each sensor integrated in the cartridge. Moreover, results show a high level of efficiency in cartridge usage. Such results are consistent with the specification of the GEM® Premier™ maintenance- free technology and are particularly relevant in the point-of-care testing setting.</p

Prevalence of Klebsiella pneumoniae strains producing carbapenemases and increase of resistance to colistin in an Italian teaching hospital from January 2012 To December 2014

The aim of this study was to characterize the spread of carbapenemase-producing Klebsiella pneumoniae (CPKP) in a tertiary level hospital using ongoing active surveillance with rectal swab cultures. Furthermore, this study analyzed the presence of CPKP in the clinical samples (CS) of a single patient as well as the evolution of Colistin-sensitive strains (CoS) to Colistin-resistant strains (CoR)

Common conditions of use elements. Atomic concepts for consistent and effective information governance

9 Pág.Myriad policy, ethical and legal considerations underpin the sharing of biological resources, implying the need for standardised and yet flexible ways to digitally represent diverse 'use conditions'. We report a core lexicon of terms that are atomic, non-directional 'concepts of use', called Common Conditions of use Elements. This work engaged biobanks and registries relevant to the European Joint Programme for Rare Diseases and aimed to produce a lexicon that would have generalised utility. Seventy-six concepts were initially identified from diverse real-world settings, and via iterative rounds of deliberation and user-testing these were optimised and condensed down to 20 items. To validate utility, support software and training information was provided to biobanks and registries who were asked to create Sharing Policy Profiles. This succeeded and involved adding standardised directionality and scope annotations to the employed terms. The addition of free-text parameters was also explored. The approach is now being adopted by several real-world projects, enabling this standard to evolve progressively into a universal basis for representing and managing conditions of use.The authors wish to thank Lotte Boormans (ERN eUROGEN) and Nawel Lalout (World Duchenne Organization) for piloting CCE terms along with DUC software. We also thank the developers of the Digital Use Conditions (DUC) structure and members of the IRDiRC ‘Machine Readable Consent and Use Conditions’ Task Force (https://irdirc.org/machine-readable-consent-and-use-conditions/) for providing project oversight and utility testing of CCEs. Finally, we acknowledge and thank the ‘European Joint Programme on Rare Diseases’ for funding this work as part of the EU Horizon 2020 programme, Grant Agreement N°825575, which contributed to the development work, supported publication costs, and resourced the IRDiRC Scientific Secretariat which is hosted at INSERM in Paris, France.Peer reviewe